Christopher Hite
Net Worth
Last updated:
What is Christopher Hite net worth?
The estimated net worth of Mr. Christopher Hite is at least $20,091,535 as of 23 Mar 2021. He owns shares worth $1,091,535 as insider and has received compensation worth at least $19,000,000 in Royalty Pharma plc.
What is the salary of Christopher Hite?
Mr. Christopher Hite salary is $3,800,000 per year as Vice Chairman & Executive Vice President in Royalty Pharma plc.
How old is Christopher Hite?
Mr. Christopher Hite is 57 years old, born in 1968.
What stocks does Christopher Hite currently own?
As insider, Mr. Christopher Hite owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Royalty Pharma plc (RPRX) | Vice Chairman & Executive Vice President | 30,541 | $35.74 | $1,091,535 |
What does Royalty Pharma plc do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Christopher Hite insider trading
Royalty Pharma plc
Mr. Christopher Hite has made only one insider trade between 2020-2021, according to the Form 4 filled with the SEC. He sold 31,959 units of RPRX stock on 23 Mar 2021.
As of 23 Mar 2021 he still owns at least 30,541 units of RPRX stock.
Royalty Pharma key executives
Royalty Pharma plc executives and other stock owners filed with the SEC:
- Dr. James Folmar Reddoch Ph.D. (55) Executive Vice President, Chief Scientific Officer and Co-Head of Research & Investments
- Mr. Christopher Hite (57) Vice Chairman & Executive Vice President
- Mr. George Wingate Lloyd (66) Executive Vice President of Investments & Gen. Counsel
- Mr. Pablo Gerardo Legorreta (61) Founder, Chairman & Chief Executive Officer